Form 4: United Therapeutics CFO James Edgemond Executes Stock Options and Sells Shares Under 10b5-1 Plan

James Edgemond, CFO of United Therapeutics, exercised stock options and sold shares of common stock on September 23, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 23, 2024, James Edgemond, the CFO and Treasurer of United Therapeutics Corp, executed stock options and sold shares of common stock.
• These transactions were conducted under a Rule 10b5-1 trading plan established on May 17, 2024.
• Edgemond exercised options at prices of $120.26 and $117.76.
• He sold shares at a price of $354.04.
• The transactions involved multiple tranches of options and shares.
• Some of the option exercises were 'sell-to-cover' transactions, where a portion of the shares obtained from exercising options were immediately sold to cover the exercise cost.
• Following these transactions, Edgemond directly owns 4,802 shares of common stock.
• Edgemond also owns 137,000 and 24,504 stock options.

Sentiment

Score: 5

Explanation: This is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests the transactions were pre-planned and doesn't necessarily reflect a change in sentiment. Therefore, the sentiment is neutral.

Industry Context

Form 4 filings are routine disclosures of transactions by company insiders and are closely monitored by investors for insights into management's perspective on the company's stock. The use of a 10b5-1 plan indicates that these transactions were pre-planned and not based on any specific non-public information at the time of the trades.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in the pharmaceutical industry, with companies like Johnson & Johnson, Pfizer, and Merck also subject to similar scrutiny.
• The use of Rule 10b5-1 trading plans is a standard method for executives to manage their stock holdings while avoiding accusations of insider trading, aligning with practices seen at companies like Amgen and Gilead Sciences.
• The size and frequency of these transactions are typical for executives at publicly traded companies, and the impact on the stock price is usually minimal unless there are unusual patterns or large-scale sales.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider trading.
• Employees are unlikely to be directly affected by these transactions.
• Customers, suppliers, and creditors are not expected to be impacted.

Key Dates